Keith Lynch joined Chondrial Therapeutics in October 2019 as the Vice President of Manufacturing and Supply Chain, bringing more than 19 years’ experience to the company. Previously, Mr. Lynch held leadership roles at a variety of pharmaceutical and biotechnology companies where he managed manufacturing and supply chain operations for multiple products at various stages of drug development. Most recently, Mr. Lynch held the position of Associate Director in the Global Technical Operations group supporting External Manufacturing at Merck and Co., Inc., where he supported the external manufacture of Keytruda® and Zinplava®. Prior to Merck, Mr. Lynch served as the Director of Manufacturing for Oncobiologics, Inc. (now Outlook Therapeutics, Inc.) a company that was focused on the development of biosimilar candidates of commercially available products like Humira® and Avastin®. Before joining Oncobiologics, he was a Director of Manufacturing at AppTec Laboratory Services, Inc. (now WuXi AppTec, Inc.) a contract development and manufacturing organization supporting companies in non-clinical and clinical development. Mr. Lynch began his career on the manufacturing floor at Immunomedics, Inc. and ImClone Systems, Inc. (now Eli Lilly and Co.) supporting the manufacture of CEA-Scan®, Leukoscan® and Erbitux®. Mr. Lynch graduated with a B.S.in Biology from Muhlenberg College, where his was president of his fraternity, Sigma Phi Epsilon.
